Andy Silvernail
Analyst · Wells Fargo. Please proceed with your question
Thanks, Mike. Good morning, everyone. I appreciate you joining us for our 2018 first quarter results. Let me start here with a brief overview. On the back of a record year, we continue to see broad-based strength in nearly every end market and continued economic improvements across the globe. I’ll elaborate more on market conditions and geographies in a minute. Favorable markets, share gains and our execution drove another record quarter. We once again delivered all-time highs in orders, sales, operating income and EPS and most of the challenges experienced in HST in the back half of 2017 have subsided. We delivered organic revenue and order growth across all three segments in the first quarter. As a company, we achieved 11% reported and 7% organic order and revenue growth. Adjusted op margin was 22.6%, up 80 basis points and adjusted EPS of $1.29 was up $0.26 or 25%. Our efforts around segmentation continue to pay dividends and when combined with our targeted growth initiatives, we see a culture across the company that is even more customer and growth focused. Our balance sheet remains very healthy. Our gross debt leverage is 1.4x and our net debt is 0.7x. If you combine our strong balance sheet, capacity of our revolver plus free cash flow and cash balances across the globe, we have the ability to deploy over $1 billion in the next 12 months should the right opportunity present itself. Now, I’d like to take a moment and talk about what we’re seeing across our markets and across the regions we do business in. Our industrial markets are robust. Day rates of our book and bill business continue to improve and we saw more project activity in the quarter signaling a pickup in CapEx spending. If you turn to our Scientific Fluidics & Optics business, demand continues to be strong for IVD/BIO and DNA sequencing markets and show early indicators of continued growth throughout the year. NIH funding in the latest federal budget was up 8.3% alleviated initial concerns of a cutback. If you look at energy, midstream oil and gas markets continue to show signs of rebound and upstream energy continues to do very well. Semicon market continues to outperform with high global demand. The first quarter we finished 15% up year-over-year. In agriculture, you may recall that we ended the previous year with a very robust preseason orders. We saw some moderate slowing in the first quarter mainly due to long winter conditions but we still managed to finish up double digit in organic revenue growth. The municipal market in the U.S. has remained very solid and we continue to see opportunities with new product development in water and investment in emerging markets within fire and rescue to capitalize on demand. Now, let’s move on to the geographic outlook. In short, the global economic outlook remains promising. The North American region continues to be positive for the vast majority of our categories. The European market is also robust with a stable political environment and all economic indices favorable for the first time in several years. Asia had accelerated with specific strength in China and in India. In summary, the growth we experienced in 2017 continued in the first quarter of 2018. And while talking about the global economy, let me talk for a second about the tariff question. Tariffs and the estimated impact have been on the top of many people’s minds here including mine. Clearly, we have to wait and see where all this settles but at this point based on the enacted Section of the 232 tariffs on March 23rd, our best estimate is that there’ll be somewhere around $2 million to $3 million of impact for the remainder of this year. This estimate excludes the Section 301 tariffs that have not been enacted. We’re looking at all of our options including pricing and alternative sourcing strategies. We’ll be very thoughtful about how we address these issues and we’ll consider the impact on both of our customers and our shareholders going forward. I also want to comment on inflation. Our team did an excellent job in the quarter driving productivity to offset inflation. However, inflation remains a concern and we will continue to work on productivity and pricing to stay ahead of it. All right, let me turn now to capital deployment. Let me take a minute to recap our commitment to our capital deployment strategy. First, our M&A pipeline continues to be robust and as I’ve mentioned previously our balance sheet positions us favorably to capitalize on the right opportunities. However, as we’ve talked about many times in the past we’ll be very disciplined in terms of capital deployment with a focus on delivering the best possible returns to our shareholders. In the meantime, we’ll work diligently on integrating our latest acquisition thinXXS into the IDEX portfolio. In terms of organic growth, the team remains dedicated to our targeted organic growth and new product development initiatives. We saw the evidence of this in the quarter where we saw strength across all three segments. This makes five quarters in a row that we saw organic revenue growth and seven quarters in a row that we saw organic order growth. Although we did not repurchase any shares in the first quarter of 2018, we remain committed to opportunistically repurchasing shares and we expect to be back in the market in the second quarter. Finally, on dividends, on April 25th, our Board approved a $0.06 increase in our quarterly dividend or a 16% overall increase from $0.37 to $0.43. This puts us at the high end of our payout ratio of 30% to 35%. All right, let’s turn now to the first quarter results. I’m on Slide 4. Q1 orders of 632 million were up 11% overall and 7% organically. This was driven by strong organic order growth across all three segments; FMT was up 7, HST was up 8 and FSD was up 5. The strength in orders gives us confidence that the remainder of 2018 as some of the orders that we saw in Q1 won’t convert to sales until the second half of the year. We’ve had excellent success driving above market growth through segmentation and target growth initiatives and we expect this to continue. Revenue of 612 million was up 11% overall and 7% organically, driven by positive organic growth across all three segments. FMT was up 5, HST up 6 and FSD up 9. Importantly, we’ve built $20 million of backlog during the quarter. The team continues to do an excellent job executing. Our flow through was 30% on sales in the quarter, excluding the impact of restructuring from both periods. And if you look at flow through, excluding impact of foreign currency, it was up even a more robust 38%. Gross margin was 45.2%, down 10 basis points from prior year mainly due to continued investments in engineering. Gross margin was up 70 basis points sequentially as the operational challenges within HST have subsided. Op margin adjusted for approximately 1.6 million of restructuring charges was up 22.6%, up 80 basis points year-over-year. The majority of the 1.6 million in restructuring was in HST and associated with our Optics Center of Excellence in Rochester, New York. Consolidated operating margin was also impacted by corporate costs being $3 million higher than the midpoint of our prior guidance. The increase in corporate costs is driven primarily by higher stock compensation, pension expense and outside consultants related to M&A and income taxes. Adjusted operating income of 138.3 million adjusted again for that 1.6 million of restructuring was up 15% compared to prior year. Q1 net income was $99 million resulting in EPS of $1.27. Excluding the impact of restructuring, adjusted EPS was $1.29 and increased $0.26 or 25% over last year. The $1.29 of adjusted EPS does include about $0.02 of pressure from a higher tax rate of 24% that compared to our ETR guidance of 22.5 and $0.04 of other income due to one-time FX transaction gains due to tax reform. We turn to free cash flow. That was one disappointment in the quarter. It was 62 million and converted at 62% of adjusted net income and was down 18% compared to prior year, primarily due to higher operating working capital. Sales in the month of March are $25 million higher than both December 2017 and February 2018 which drove the majority of the increase in receivables. Inventory also grew as we source additional raw materials to ensure we can meet customers’ demands. All right, let me turn now to the segment discussion if you’ll turn to Slide 5, I’m going to start with Fluid & Metering. FMT continued to remain strong with both order and revenue growth. Q1 orders were up 9% overall, 7% organically. Sales were up 7% overall, 5% organically. Op margin adjusted for restructuring was 28.5%, up 110 basis points over last year. If you look at ag, it remains strong with double digit revenue increases year-over-year. On the industrial side, pumps had a very impressive quarter with double-digit increases in both orders and sales year-over-year. The increased oil prices have driven more business in the global oil and gas market as well as our LACT business. And importantly, our U.S. distribution market is solid and day rates for our book and ship continue to improve. In our industrial valves business, the highlight for the quarter was really in China where we saw a robust market. In water, it remains well positioned to grow via new products. And in energy, also a great new product story. We’re seeing aviation show signs of recovery and the cold winter drove strong truck builds for the segment. Let’s move on to Health & Science. I’m on Slide 6. I was very pleased with the Health & Science first quarter. Q1 orders were up 14% overall, 8% organically. Revenues were up 11% overall, 6% organically. Excluding the impact of the restructuring expense, adjusted op margin was 23.9%, an increase of 120 basis points over the first quarter of last year mostly due to higher volume and productivity initiatives and it was 160 basis points sequentially as operational challenges that we discussed last year have subsided. The 23.9% operating margin is much closer to where I expect the segment to be performing overall and I’m very pleased with how the team executed in the quarter. If we look at the Life Science & Optics business, again, IVD/BIO end markets remained strong. We saw some earlier than expected FDA approvals for our customers who drove favorability in the first quarter. And as I said, the integration of thinXXS is going quite well, very happy to have them on board. If you look at Sealing Solutions, the semiconductor market continues to be very strong globally as well as its transportation market. The Sealing Solutions group led the entire segment in terms of growth. MPT had a strong quarter with an improving funnel of opportunities and projects. And then finally in HST industrial, we saw nice growth across multiple markets and importantly we’re seeing the distribution business within HST perform very well. I’m on our last segment, Diversified, Slide 7. Orders were up 11% overall, 5% organically in the first quarter. Revenues were up 16% overall and up 9% organically. Excluding restructuring expenses, adjusted op margin was 24.9% which increased 110 basis points in the first quarter. In dispensing, the North American and the European markets remained strong with new products performing very well. Project activity in emerging markets is also positive. Looking at Fire & Safety, we saw rescue which is very positive across the globe and we’ve seen project activity pick up in India, China and the Middle East. In the Fire business, we’ve seen strength in OEM and the muni business which has remained pretty steady. And margin improvements for Akron Brass and AWG continue to be ahead of expectations. Finally on Band-IT, we had double-digit organic order and revenue growth in the quarter. We saw our share gains across global regions through new products and new program wins. And then finally, we are cautiously watching the impact of tariffs on Band-IT. Most of its supply chain is domestic but an increase in demand for U.S. produced alloys could have an impact. Let me now conclude with some additional details regarding our 2018 guidance for the second quarter and for the full year. I’m on Slide 8. In Q2, we’re estimating EPS to be $1.30 to $1.32 with organic revenue growth in the range of 5% to 6% and operating margin around 22.5%. The Q2 effective tax rate is expected to be approximately 22.5% with an estimated 3% top line tailwind from FX based on the March 31st rates. Corporate costs for Q2 are expected to be about $20 million. If you turn to the full year 2018, we’ve increased our full year guidance to $5.05 to $5.20. That’s the new range. Full year organic revenue growth is expected to be in the range of 5% to 6% which is an increase from our previous guidance. Full year operating margin is expected to be in the range of 22.5% to 23%. We also expect to see about a 3% overall tailwind from FX based on the March 31st rates. The full year effective tax rate is expected to be 23%. But as the IRS continues to interpret tax reform, we could see some more variability in taxes throughout 2018. CapEx is anticipated to be around $50 million and free cash flow will remain strong at about 110% of net income. Finally, corporate costs are expected to be in the range of $73 million to $77 million for the year. This is a $3 million higher number compared to the guidance we’d given before, all of it which occurred in the first quarter. Finally, our earnings guidance excludes any impact from associated costs or impact from acquisitions or restructuring in the quarter. With that, let me pause here. And operator, let me turn it over for questions.